This inventor holds 1 USPTO granted patent. Top assignee: Council of Scientific and Industrial Research. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: Jitendra Kumar Kanuajiya: Innovator in Anti-Leukemic Research
Introduction
Jitendra Kumar Kanuajiya is a notable inventor based in Lucknow, India. He has made significant contributions to the field of medical research, particularly in the area of leukemia treatment. His innovative work has led to the development of a unique anti-leukemic agent that shows promise in inducing differentiation in myeloid leukemia cells.
Latest Patents
Kanuajiya holds a patent for an anti-leukemic agent, specifically the compound Ormeloxifene. This compound is identified as [3, 4-trans-2,2-dimethyl-3-phenyl-4-p-(beta-pyrrolidinoethoxy) phenyl-7-methoxy chroman]. The invention provides a solution for inducing differentiation in various types of myeloid leukemias, including acute promyelocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. The differentiation induced by Ormeloxifene is marked by an increase in differentiation marker proteins such as C/EBPα and surface proteins like cd11b and granulocyte colony-stimulating factor receptor (GCSFr).
Career Highlights
Kanuajiya is affiliated with the Council of Scientific and Industrial Research, where he conducts his research. His work has been instrumental in advancing the understanding of myeloid leukemia and exploring new therapeutic avenues. He has demonstrated that Ormeloxifene can induce differentiation in myeloid leukemia cells, with varying effects based on dosage. At higher doses, there is an early onset of differentiation accompanied by apoptotic effects, while lower doses induce differentiation over a longer duration with reduced apoptosis.
Collaborations
Kanuajiya has collaborated with notable colleagues, including Pooja Pal and Sabyasachi Sanyal. Their combined efforts contribute to the ongoing research and development in the field of leukemia treatment.
Conclusion
Jitendra Kumar Kanuajiya's innovative research in anti-leukemic agents highlights the potential for new treatments in the fight against leukemia. His contributions are paving the way for advancements in medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile